Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Accurate Diagnosis of Multiple Sclerosis Using Hybrid Positron Emission Tomography/Magnetic Resonance (PET/MR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04521439
Recruitment Status : Not yet recruiting
First Posted : August 20, 2020
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
Ruijin Hospital

Brief Summary:

Multiple sclerosis (MS) is an immune-mediated chronic inflammatory demyelinating disease of the central nervous system. Its main feature is progressive demyelination, which ultimately leads to axon damage and neuron loss. MR is the main imaging technique in the current diagnostic criteria of MS. The conventional MR sequence recommended in this diagnostic criteria has high sensitivity for detecting demyelination and axon damage, but has poor specificity, which makes disease modification therapy (DMT) blind, and it is also difficult to accurately determine the long-term prognosis.

PET is a non-invasive molecular imaging technology that can quantitatively monitor physiological or pathological processes in vivo. 18F-labeled thioflavin derivative probe (18F-florbetapir) can bind to myelin basic protein in the white matter, providing quantitative assessment of myelin content. Our preliminary studies have confirmed that the uptake of 18F-florbetapir in MS lesions is significantly related to the myelin content measured by histological staining. Therefore, 18F-florbetapir PET may be a very effective myelin imaging technology.

Advanced MR sequence such as magnetic resonance spectroscopy (MRS) can evaluate axonal damage by analyzing neuronal activity marker N-acetyl aspartate (NAA). The new whole-brain fast 3D MRS sequence breaks through the bottleneck of low signal-to-noise ratio and spatial resolution of the current MRS sequence, and provides a reliable method for obtaining neuronal activity markers in the three-dimensional space of MS sporadic lesions in the whole brain.

Integrated PET/MR makes PET detector implant in the MR magnet, which realizes the simultaneous acquisition of PET and MR in one scan, ensuring the high consistency of the two modes. This makes it possible to simultaneously analyze PET and MRS quantitative parameters in multiple and different sizes of MS lesions, that is, to obtain two different pathological features of demyelination and neuronal damage. Separating these two pathological changes will help to more accurately and quantitatively evaluate the efficacy of DMT, program selection and prognostic judgment.

This project intends to recruit 30 MS patients between 18-65 years old, and 30 healthy volunteers with matched age and sex as normal controls. PET/MR imaging, serological examination and cerebrospinal fluid testing and scale evaluation will be performed. The aim of this project is to planned to establish a new imaging evaluation technology for accurate diagnosis and prognosis evaluation of MS.


Condition or disease Intervention/treatment Phase
Multiple Sclerosis Diagnostic Test: 18F-florbetapir PET+MRSI Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Hybrid PET/MR Imaging to Assess Demyelination and Axonal Injury in Multiple Sclerosis
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : March 30, 2022
Estimated Study Completion Date : September 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MS Patients Group Diagnostic Test: 18F-florbetapir PET+MRSI
PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.

Sham Comparator: Healthy Volunteers Group Diagnostic Test: 18F-florbetapir PET+MRSI
PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.




Primary Outcome Measures :
  1. Distribution Volume Ratio (DVR) [ Time Frame: Baseline ]
    Dynamic parameter of 18F-florbetapir distribution for quantitatively assessing the demyelination

  2. Change from Baseline DVR at 6 months [ Time Frame: 6 months after baseline ]
    Change of 18F-florbetapir distribution in the demyelinated lesions after 6 months

  3. Change from Baseline DVR at 1 year [ Time Frame: 1 year after baseline ]
    Change of 18F-florbetapir distribution in the demyelinated lesions after 1 year

  4. Standardized Uptake Value Ratio (SUVR) [ Time Frame: Baseline ]
    Static parameter of 18F-florbetapir uptake for quantitatively assessing the demyelination

  5. Change from Baseline SUVR at 6 months [ Time Frame: 6 months after baseline ]
    Change of 18F-florbetapir uptake in the demyelinated lesions after 6 months

  6. Change from Baseline SUVR at 1 year [ Time Frame: 1 year after baseline ]
    Change of 18F-florbetapir uptake in the demyelinated lesions after 1 year

  7. N-acetyl aspartate (NAA) quantification [ Time Frame: Baseline ]
    Neuronal activity marker based on magnetic resonance spectroscopy imaging (MRSI)

  8. Change from Baseline NAA at 6 months [ Time Frame: 6 months after baseline ]
    Change of neuronal activity marker in the demyelinated lesions after 6 months

  9. Change from Baseline NAA at 1 year [ Time Frame: 1 year after baseline ]
    Change of neuronal activity marker in the demyelinated lesions after 1 year



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

MS Patients Group:

Inclusion Criteria:

  • between 18-65 years old;
  • diagnosed with mild or moderate disease (EDSS score ≤ 5 points); it meets the 2017 new version of McDonald diagnostic criteria for multiple sclerosis.
  • meet the diagnostic criteria of clinically isolated syndromes (CIS)

Exclusion Criteria:

  • No brain surgery/no brain trauma/no history of brain disease (stroke), no other independent neurological or psychiatric history;
  • No severe depression symptoms;
  • No alcoholism or drug dependence (addiction);
  • No other conditions that affect the smooth progress of the inspection: such as hearing impairment, comprehension impairment, poor compliance, etc.;
  • No rheumatic diseases and other acute or chronic inflammations (required for hematological markers).
  • No MR contrast agent allergy

Healthy Volunteers Group:

Inclusion Criteria:

  • between 18-65 years old;
  • able to understand the purpose of clinical research and test plan;
  • In the brain MR assessment, it is judged as "normal (corresponding to age)"

Exclusion Criteria:

  • Any major mental illness; history of schizophrenia or schizoaffective disorder
  • Any important neurological disease, such as cerebrovascular disease, inflammation or infectious disease, demyelinating disease, neurodegenerative disease, history of epilepsy or history of physical or craniocerebral trauma or brain surgery or intracranial hematoma with permanent brain history of injury;
  • Brain MR has pathological manifestations;
  • Any major diseases or unstable conditions (such as unstable angina, myocardial infarction or coronary revascularization within 12 months before enrollment, heart failure, chronic renal failure, chronic liver disease, severe lung disease, blood disease, poorly controlled diabetes, chronic infections);
  • Medical history of tumors (except skin or prostate cancer in situ) within 5 years before screening;
  • High risk of drug allergy (such as patients with allergic asthma) or history of severe allergic reactions to allergens;
  • History of alcohol or drug abuse/dependence;
  • MR contraindications (such as pacemaker or nerve stimulator or metal foreign body, high fever, etc.)
Layout table for additonal information
Responsible Party: Ruijin Hospital
ClinicalTrials.gov Identifier: NCT04521439    
Other Study ID Numbers: PET/MR-MS
First Posted: August 20, 2020    Key Record Dates
Last Update Posted: August 20, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases